Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PBI Awarded RA Research Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

PBI Awarded RA Research Contract

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pacific Biometrics, Inc. (PBI) has been awarded a $1.2 million contract with a top pharmaceutical company related to a biological treatment for rheumatoid arthritis (RA). Under the contract, PBI will provide lab data and autoantibody testing for a global Phase III program. The sponsor plans to submit a NDA with the FDA and equivalent filings with regulatory agencies in other countries. Testing is expected to begin in Q32007 and may extend as long as five years.

“Our inclusion in this pivotal, international Phase III arthritis program is exciting on multiple fronts,” said Ron Helm, chief executive officer of PBI. “These studies will further strengthen our relationship with this sponsor, who accounts for an important and growing percentage of our more diversified customer base. Furthermore, our selection for this project is validation for our worldwide, best-in-class testing of biomarkers as they relate to the diagnosis and treatment of arthritis — a growing area of expertise for the company. Finally, assuming the scope of the studies remains unchanged, the contract should have a meaningful impact on our fiscal 2008 financial results.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics